P14.66 TTFields dose distribution and tumor growth patterns confirm clinical activity of TTFields: MRI analysis of the randomized phase 3 EF-14 trial

Por Kebir, S, Ballo, M T, Jeyapalan, S, Toms, S A, Hottinger, A, Pollom, E, Glas, M
Publicado no Neuro Oncol (2019)

P01.102 Cost effectiveness of treating glioblastoma patients age 65 years or older with Tumor Treating Fields plus Temozolomide versus Temozolomide alone

Por Guzauskas, G F, Wang, B C M, Pollom, E L, Stieber, V W, Kinzel, A, Proescholdt, C, Garrison, L
Publicado no Neuro Oncol (2018)